Results 91 to 100 of about 19,815 (203)
α‐Synuclein in Parkinson's Disease: From Bench to Bedside
Medicinal Research Reviews, Volume 45, Issue 3, Page 909-946, May 2025.ABSTRACT α‐Synuclein (α‐syn), a pathological hallmark of PD, is emerging as a bridging element at the crossroads between neuro/immune‐inflammatory responses and neurodegeneration in PD. Several evidence show that pathological α‐syn accumulates in neuronal and non‐neuronal cells (i.e., neurons, microglia, macrophages, skin cells, and intestinal cells ...
Gabriele Bellini +8 more
wiley +1 more source
Inhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia-positive and negative acute lymphoblastic leukemia. [PDF]
PLoS ONE, 2014 Nilotinib is a selective BCR-ABL tyrosine kinase inhibitor related to imatinib that is more potent than imatinib. Nilotinib is widely used to treat chronic myelogenous leukemia (CML) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). The
Hailong Zhang +4 more
doaj +1 more source
Drug target optimization in chronic myeloid leukemia using innovative computational platform. [PDF]
, 2015 Chronic Myeloid Leukemia (CML) represents a paradigm for the wider cancer field. Despite the fact that tyrosine kinase inhibitors have established targeted molecular therapy in CML, patients often face the risk of developing drug resistance, caused by ...
Benque, David +10 more
core +2 more sources
Progression significance for low‐level aberrant B‐lymphoblasts in chronic myeloid leukaemia patients
Clinical and Translational Medicine, Volume 15, Issue 11, November 2025.
Haoren Wang +12 more
wiley +1 more source
Chlorogenic Acid: An In‐Depth Review of Its Effectiveness in Cancer Treatment
Cancer Nexus, Volume 1, Issue 1, April 2025.ABSTRACT Cancer remains a formidable global health challenge. Owing to the unsatisfactory curative effects and severe side effects, it is urgent to explore safer and more effective therapeutic alternatives and drugs. Chlorogenic acid (CGA), a natural polyphenol, has emerged as a promising candidate for cancer therapy due to its multiple functions and ...
Bin Wang +9 more
wiley +1 more source
Case Reports in OncologyIntroduction: Chronic myeloid leukemia (CML) is a myeloproliferative disease caused by the reciprocal translocation of chromosomes 9 and 22, which leads to a chimeric gene product known as BCR-ABL.
Darshankumar M. Raval +3 more
doaj +1 more source
Advances in reversible covalent kinase inhibitors
Medicinal Research Reviews, Volume 45, Issue 2, Page 629-653, March 2025.Abstract Reversible covalent kinase inhibitors (RCKIs) are a class of novel kinase inhibitors attracting increasing attention because they simultaneously show the selectivity of covalent kinase inhibitors yet avoid permanent protein‐modification‐induced adverse effects.
Zheng Zhao, Philip E. Bourne
wiley +1 more source
Biologics: Targets & Therapy, 2016 Josephine Emole,1 Taiwo Talabi,2 Javier Pinilla-Ibarz1 1Department of Malignant Hematology, 2Moffitt Program for Outreach Wellness Education and Resources, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA Abstract: Chronic myelogenous ...
Emole J, Talabi T, Pinilla-Ibarz J
doaj
Revista Brasileira de Hematologia e Hemoterapia, 2015 Background: Chronic myeloid leukemia is a myeloproliferative disorder characterized by the Philadelphia chromosome or t(9;22)(q34.1;q11.2), resulting in the break-point cluster regionAbelson tyrosine kinase fusion gene, which encodes a constitutively ...
Maria de Lourdes Lopes Ferrari Chauffaille +2 more
doaj +1 more source
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenetic response after interferon-alpha results in any high complete molecular response. [PDF]
, 2008 To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic myeloid leukaemia (CP-CML) patients responsive to interferon-alpha (IFNα), in stable complete cytogenetic response (CCR) but with persistent PCR positivity.
B. De Angelis +14 more
core +1 more source